Trekka Therapeutics, LLC

Saint Paul, MN · Biotech · Private

Therapeutic cancer vaccine targeting mutated BRAF V600E neoantigen peptide combined with resiquimod adjuvant for melanoma immunotherapy

Grants
$961K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform$547,802
Federal grantDepartment of Health and Human Services · Phase I · Nanodroplet Infused Analgesic-Wafer for Transmucosal Opioid-free Treatment of Subacute Oral Pain$413,298
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2540Addition Therapeutics—$28M
2541NBO Pharma Inc.—$7.6M
2542Apriori Bio——
2543Trekka Therapeutics, LLC——
2544Rare Air Health, Inc.—$4.7M
2545Neela Therapeutics, Inc.—$12M
2546Regenerate, Inc.—$2.3M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.